Arthritis & Rheumatism
Papers 10000
1 page of 1,000 pages (10k results)
#1Liana Fraenkel (Yale University)H-Index: 42
#2Joan M. Bathon (NewYork–Presbyterian Hospital)H-Index: 2
Last. Gail S. Kerr (HU: Howard University)H-Index: 16
view all 0 authors...
OBJECTIVE To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. METHODS We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and stren...
2 CitationsSource
#1Atul Deodhar (OHSU: Oregon Health & Science University)H-Index: 52
#2Désirée van der Heijde (LUMC: Leiden University Medical Center)H-Index: 122
Last. Yunxia Sui (AbbVie)H-Index: 1
view all 0 authors...
Objective null To report efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). null Methods null In the SELECT-AXIS 1 study, adults with active AS and inadequate response to non-steroidal anti-inflammatory drugs were randomized to upadacitinib 15 mg once daily (QD) or placebo. At week 14, patients continued in the open-label extension and received upadacitinib up to week 104; reported here are interim data up to week 64. null Results null Of 187 patient...
1 CitationsSource
A 42-year old caucasian woman presented herself in our ER with a one week history of rash on the lower limbs, which had first appeared 4 days after vaccination with the BioNTECH/Pfizer SARS-CoV2 vaccine. The rash - with the typical appearance of a cutaneous small vessel vasculitis (CSVV) (figure 1) - spread from the lower limbs up to the gluteal area over a few days. Application of topical steroids had led to no improvement. Physical examination showed no other pathologies - except for hypertens...
#1David Simon (FAU: University of Erlangen-Nuremberg)H-Index: 16
#2Koray Tascilar (FAU: University of Erlangen-Nuremberg)H-Index: 15
Last. Florian SchuchH-Index: 5
view all 0 authors...
Objective null B cell depletion is an established therapeutic principle in a wide range of autoimmune disease. However, B cells are also critical for inducing protective immunity after infection and vaccination. We therefore assessed humoral and cellular immune responses after infection with or vaccination against severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) in B cell depleted patients and B cell competent healthy controls. null Methods null Antibody (ELISA) and T cell (IFNγ ELI...
#1Nicolino Ruperto (Istituto Giannina Gaslini)H-Index: 82
#2Alberto Martini (UniGe: University of Genoa)H-Index: 106
Last. Angela Pistorio (Istituto Giannina Gaslini)H-Index: 73
view all 0 authors...
Until the end of the last century there were no drugs approved for the treatment of juvenile idiopathic arthritis (JIA). This situation was revolutionized in the past 20 years thanks to 3 factors: the introduction in the USA and in Europe of paediatric legislations(1, 2), the availability of biologic disease-modifying anti-rheumatic drugs (b-DMARDs), and the existence of not-for-profit organizations with the mission to foster, facilitate and co-ordinate the development, conduct, analysis, and re...
#1Jonas Fischer (University of Würzburg)H-Index: 1
#2Johannes Dirks (University of Würzburg)H-Index: 1
Last. Henner Morbach (University of Würzburg)H-Index: 29
view all 0 authors...
OBJECTIVES Antinuclear antibody (ANA) positive Juvenile Idiopathic Arthritis (JIA) is characterized by synovial B cell hyperactivity, but the precise role of CD4+ T cells in promoting local B cell activation is unknown. The objective of this study is to unravel the phenotype and function of synovial CD4+ T cells that promote the aberrant B cell activation in JIA. METHODS Flow cytometric analysis was performed to compare the phenotype and cytokine pattern of synovial fluid (SF) PD-1hi CD4+ T cell...
We read with great interest article on "Is treatment in patients with suspected non-radiographic axial spondyloarthritis effective? Six-months results of a placebo controlled trial" by Rusman T et al[1] . It was an interestingly planned study where based on clinical disease activity as per BASDAI, patients with nr-ax SpA were randomized either to receive etanercept or placebo for 16 weeks. Results of this study bring forth many doubts on our currently prevalent assessment of disease activity in ...
#1Chun Yu Lin (NCKU: National Cheng Kung University)H-Index: 3
Last. Chung-Yuan Hsu (CGU: Chang Gung University)H-Index: 9
view all 0 authors...
Objective null To determine the risk and time trends of hospitalized heart failure (HF) in individuals with newly diagnosed polymyositis (PM) and dermatomyositis (DM) at the general population level. null Methods null We conducted a retrospective cohort study using a nationwide insurance database in Taiwan. Patients with incident PM/DM and without previous histories of HF were selected between 2000 and 2013. Unmatched and propensity score-matched cohorts were established separately. Multivariabl...
#1T. Rusman (VUMC: Vanderbilt University Medical Center)H-Index: 1
#2M. A. C. Van der Weijden (VUMC: Vanderbilt University Medical Center)H-Index: 1
Last. I E van der Horst-Bruinsma (VUMC: Vanderbilt University Medical Center)H-Index: 35
view all 0 authors...
We would like to thank our colleagues for their comments on our paper "Is treatment with suspected non-radiographic axial spondyloarthritis effective? Six-month results of a placebo-controlled trial with etanercept".
#1Christine Liu (NIH: National Institutes of Health)H-Index: 2
#2Jacqueline Kieltyka (NIH: National Institutes of Health)H-Index: 2
Last. John J. O'Shea (NIH: National Institutes of Health)H-Index: 134
view all 0 authors...
The discovery of cytokines and their role in immune and inflammatory disease led to the development a plethora of targeted biologic therapies. Later, efforts to understand mechanisms of cytokine signal transduction led to the discovery of Janus kinases (JAKs), which themselves were quickly identified as therapeutic targets. It has been a decade since the first JAK inhibitors (jakinibs) were approved and now there are nine jakinibs approved for treatment of rheumatologic, dermatologic, hematologi...
Top fields of study
Rheumatoid arthritis
Diabetes mellitus